Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Nutriband Inc. develops transdermal pharmaceutical products, focusing on abuse-deterrent patches for opioids and stimulants. Its core technology, AVERSA, aims to reduce drug abuse, misuse, and accidental exposure. The company collaborates with contract manufacturers and research organizations, targeting markets in the U.S. and internationally. Its business model emphasizes innovative drug delivery systems, regulatory approval pathways, and intellectual property protection to address unmet needs in pain management and addiction treatment.
This description was generated via AI from an annual report. Updated about 1 year ago.